United States (USA)-Molecular Diagnostics Market, Test Volume Forecast & Companies
Molecular diagnostics is a rapidly–advancing area of research and medicine, with new technologies and applications being added continuously. Molecular diagnostics is the promising area which can transform disease diagnosis, as diagnosis based on symptoms and use of surrogate markers is replaced by genomic and proteomic analysis. This fundamental shift offers the promise for early disease detection, potentially before symptoms have even occurred.
United States molecular diagnostic market for 2018 is anticipated to more than double from its current value in 2013. In United States molecular diagnostic market, infectious disease controls the highest market share in 2013.
But in terms of test volume food pathogen testing takes the lead pushing infectious disease at number two position.
Molecular oncology tests have emerged as a significant rapidly growing market segment. In the current medical diagnostics market, molecular diagnostics for cancer testing offers one of the brightest areas for growth and innovation. United States constitutes the largest regional market for blood screening and blood products. Molecular diagnostics is also starting to emerge as an important tool for HLA Testing, Food Pathogen Detection Testing and other disease areas.
In companies market share Hologic Inc., Myriad Genetics and Becton Dickinson together these 3 companies control more than 50% market share for 2013. However Becton Dickinson is expected to lose its market share gradually and Roche is expected to take its place by 2018.
United States Molecular Diagnostics Market & Test Volume – Application Segment Analysis (2010 – 2018)
1. Oncology Testing
a) Breast Cancer
b) Colorectal Cancer
c) Prostate Cancer
d) Others
2. Infectious Diseases
a) Virology Testing
b) HPV Testing
c) HAI Testing
d) Critical Care Testing
3. Genetic Testing
4. Blood Screening
5. Food Pathogen Testing
6. Tissue Typing (HLA Testing)
United States Molecular Diagnostics – Company Wise Sales Analysis (2010 – 2018)
1. Roche
2. Abbott
3. Myriad Genetics
4. BioMerieux
5. Qiagen
6. Hologic Inc.
7. Becton Dickinson
8. Siemens
9. Cepheid
10. Others
Renub Research study titled “United States (USA)-Molecular Diagnostics Market, Test Volume Forecast & Companies” provides a comprehensive assessment of the fast–evolving, high–growth Global Molecular Diagnostics Market. This 128 page report with 87 Figures studies the United States Molecular Diagnostics from 4 view points: 1) Market and Forecast 2) Application Wise Market & Forecast 3) Application Wise Test Volume & Forecast 4) Company Wise Molecular Diagnostics Sales & Forecast
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 100 paid databases.
United States molecular diagnostic market for 2018 is anticipated to more than double from its current value in 2013. In United States molecular diagnostic market, infectious disease controls the highest market share in 2013.
But in terms of test volume food pathogen testing takes the lead pushing infectious disease at number two position.
Molecular oncology tests have emerged as a significant rapidly growing market segment. In the current medical diagnostics market, molecular diagnostics for cancer testing offers one of the brightest areas for growth and innovation. United States constitutes the largest regional market for blood screening and blood products. Molecular diagnostics is also starting to emerge as an important tool for HLA Testing, Food Pathogen Detection Testing and other disease areas.
In companies market share Hologic Inc., Myriad Genetics and Becton Dickinson together these 3 companies control more than 50% market share for 2013. However Becton Dickinson is expected to lose its market share gradually and Roche is expected to take its place by 2018.
United States Molecular Diagnostics Market & Test Volume – Application Segment Analysis (2010 – 2018)
1. Oncology Testing
a) Breast Cancer
b) Colorectal Cancer
c) Prostate Cancer
d) Others
2. Infectious Diseases
a) Virology Testing
b) HPV Testing
c) HAI Testing
d) Critical Care Testing
3. Genetic Testing
4. Blood Screening
5. Food Pathogen Testing
6. Tissue Typing (HLA Testing)
United States Molecular Diagnostics – Company Wise Sales Analysis (2010 – 2018)
1. Roche
2. Abbott
3. Myriad Genetics
4. BioMerieux
5. Qiagen
6. Hologic Inc.
7. Becton Dickinson
8. Siemens
9. Cepheid
10. Others
Renub Research study titled “United States (USA)-Molecular Diagnostics Market, Test Volume Forecast & Companies” provides a comprehensive assessment of the fast–evolving, high–growth Global Molecular Diagnostics Market. This 128 page report with 87 Figures studies the United States Molecular Diagnostics from 4 view points: 1) Market and Forecast 2) Application Wise Market & Forecast 3) Application Wise Test Volume & Forecast 4) Company Wise Molecular Diagnostics Sales & Forecast
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 100 paid databases.
1. EXECUTIVE SUMMARY
2. UNITED STATES MOLECULAR DIAGNOSTICS MARKET, TEST VOLUME & FORECAST (2010 – 2018)
2.1 United States Molecular Diagnostics Market & Forecast
2.2 United States Molecular Diagnostics Test Volume & Forecast
3. UNITED STATES MOLECULAR DIAGNOSTICS MARKET & VOLUME SHARE (2010 – 2018)
3.1 United States Molecular Diagnostics Market Share & Forecast – Application Wise
3.2 United States Molecular Diagnostics Market Share & Forecast – Company Wise
3.3 United States Molecular Diagnostics Test Volume Share & Forecast – Application Wise
4. UNITED STATES MOLECULAR DIAGNOSTICS MARKET & FORECAST – APPLICATION WISE
4.1 Oncology Testing Market (2004 – 2018)
4.1.1 Breast Cancer Testing Market (2004 – 2018)
4.1.2 Colorectal Cancer Testing Market (2004 – 2018)
4.1.3 Prostate Cancer Testing Market (2004 – 2018)
4.1.4 Other Cancer Testing Market (2004 – 2018)
4.2 Infectious Disease Testing Market (2010 – 2018)
4.2.1 Virology Testing Market (2007 – 2018)
4.2.2 HPV Testing Market (2004 – 2018)
4.2.3 HAI Testing Market (2010 – 2018)
4.2.4 Critical Care Testing Market (2010 – 2018)
4.3 Genetic Testing Market (2010 – 2018)
4.4 Blood Screening Market (2006 – 2018)
4.5 Food Pathogen Testing Market (2010 – 2018)
4.6 Tissue Typing (HLA) Testing Market (2008 – 2018)
5. UNITED STATES MOLECULAR DIAGNOSTICS TEST VOLUME – APPLICATION WISE
5.1 Oncology Test Volume (2004 – 2018)
5.1.1 Breast Cancer Test Volume (2004 – 2018)
5.1.2 Colorectal Cancer Test Volume (2004 – 2018)
5.1.3 Prostate Cancer Test Volume (2004 – 2018)
5.1.4 Other Cancer Test Volume (2004 – 2018)
5.2 Infectious Disease Test Volume (2010 – 2018)
5.2.1 Virology Test Volume (2007 – 2018)
5.2.2 HPV Test Volume (2004 – 2018)
5.2.3 HAI Test Volume (2010 – 2018)
5.2.4 Critical Care Test Volume (2010 – 2018)
5.3 Genetic Testing Test Volume & Forecast (2010 – 2018)
5.4 Blood Screening Test Volume & Forecast (2006 – 2018)
5.5 Food Pathogen Test Volume & Forecast (2010 – 2018)
5.6 HLA Test Volume & Forecast (2008 – 2018)
6. UNITED STATES MOLECULAR DIAGNOSTICS MARKET – COMPANY WISE
6.1 Roche – United States Molecular Diagnostic Sales and Forecast
6.2 Abbott Laboratories – United States Molecular Diagnostic Sales and Forecast
6.3 Myriad Genetics – United States Molecular Diagnostic Sales and Forecast
6.4 Biomerieux – United States Molecular Diagnostic Sales and Forecast
6.5 Qiagen – United States Molecular Diagnostic Sales and Forecast
6.6 Hologic Inc. (Acquired Gen–Probe) – United States Molecular Diagnostic Sales and Forecast
6.7 Becton Dickinson – United States Molecular Diagnostic Sales and Forecast
6.8 Siemens – United States Molecular Diagnostic Sales and Forecast
6.9 Cepheid – United States Molecular Diagnostic Sales and Forecast
6.10 Others – United States Molecular Diagnostic Sales and Forecast
7. UNITED STATES MOLECULAR DIAGNOSTICS MARKET – DRIVING FACTORS
7.1 Point A
7.2 Point B
7.3 Point C
8. UNITED STATES MOLECULAR DIAGNOSTICS MARKET – CHALLENGES
8.1 Point A
8.2 Point B
8.3 Point C
2. UNITED STATES MOLECULAR DIAGNOSTICS MARKET, TEST VOLUME & FORECAST (2010 – 2018)
2.1 United States Molecular Diagnostics Market & Forecast
2.2 United States Molecular Diagnostics Test Volume & Forecast
3. UNITED STATES MOLECULAR DIAGNOSTICS MARKET & VOLUME SHARE (2010 – 2018)
3.1 United States Molecular Diagnostics Market Share & Forecast – Application Wise
3.2 United States Molecular Diagnostics Market Share & Forecast – Company Wise
3.3 United States Molecular Diagnostics Test Volume Share & Forecast – Application Wise
4. UNITED STATES MOLECULAR DIAGNOSTICS MARKET & FORECAST – APPLICATION WISE
4.1 Oncology Testing Market (2004 – 2018)
4.1.1 Breast Cancer Testing Market (2004 – 2018)
4.1.2 Colorectal Cancer Testing Market (2004 – 2018)
4.1.3 Prostate Cancer Testing Market (2004 – 2018)
4.1.4 Other Cancer Testing Market (2004 – 2018)
4.2 Infectious Disease Testing Market (2010 – 2018)
4.2.1 Virology Testing Market (2007 – 2018)
4.2.2 HPV Testing Market (2004 – 2018)
4.2.3 HAI Testing Market (2010 – 2018)
4.2.4 Critical Care Testing Market (2010 – 2018)
4.3 Genetic Testing Market (2010 – 2018)
4.4 Blood Screening Market (2006 – 2018)
4.5 Food Pathogen Testing Market (2010 – 2018)
4.6 Tissue Typing (HLA) Testing Market (2008 – 2018)
5. UNITED STATES MOLECULAR DIAGNOSTICS TEST VOLUME – APPLICATION WISE
5.1 Oncology Test Volume (2004 – 2018)
5.1.1 Breast Cancer Test Volume (2004 – 2018)
5.1.2 Colorectal Cancer Test Volume (2004 – 2018)
5.1.3 Prostate Cancer Test Volume (2004 – 2018)
5.1.4 Other Cancer Test Volume (2004 – 2018)
5.2 Infectious Disease Test Volume (2010 – 2018)
5.2.1 Virology Test Volume (2007 – 2018)
5.2.2 HPV Test Volume (2004 – 2018)
5.2.3 HAI Test Volume (2010 – 2018)
5.2.4 Critical Care Test Volume (2010 – 2018)
5.3 Genetic Testing Test Volume & Forecast (2010 – 2018)
5.4 Blood Screening Test Volume & Forecast (2006 – 2018)
5.5 Food Pathogen Test Volume & Forecast (2010 – 2018)
5.6 HLA Test Volume & Forecast (2008 – 2018)
6. UNITED STATES MOLECULAR DIAGNOSTICS MARKET – COMPANY WISE
6.1 Roche – United States Molecular Diagnostic Sales and Forecast
6.2 Abbott Laboratories – United States Molecular Diagnostic Sales and Forecast
6.3 Myriad Genetics – United States Molecular Diagnostic Sales and Forecast
6.4 Biomerieux – United States Molecular Diagnostic Sales and Forecast
6.5 Qiagen – United States Molecular Diagnostic Sales and Forecast
6.6 Hologic Inc. (Acquired Gen–Probe) – United States Molecular Diagnostic Sales and Forecast
6.7 Becton Dickinson – United States Molecular Diagnostic Sales and Forecast
6.8 Siemens – United States Molecular Diagnostic Sales and Forecast
6.9 Cepheid – United States Molecular Diagnostic Sales and Forecast
6.10 Others – United States Molecular Diagnostic Sales and Forecast
7. UNITED STATES MOLECULAR DIAGNOSTICS MARKET – DRIVING FACTORS
7.1 Point A
7.2 Point B
7.3 Point C
8. UNITED STATES MOLECULAR DIAGNOSTICS MARKET – CHALLENGES
8.1 Point A
8.2 Point B
8.3 Point C
LIST OF FIGURES:
Figure 2–1: United States – Molecular Diagnostics Market (Million US$), 2010 – 2013
Figure 2–2: United States – Forecast for Molecular Diagnostics Market (Million US$), 2014 – 2018
Figure 2–3: United States – Molecular Diagnostics Test Volume (Million), 2010 – 2013
Figure 2–4: United States – Forecast for Molecular Diagnostics Test Volume (Million), 2014 – 2018
Figure 3–1: United States – Molecular Diagnostics Applications Market Share (Percent), 2010 – 2013
Figure 3–2: United States – Forecast for Molecular Diagnostics Applications Market Share (Percent), 2014 – 2018
Figure 3–3: United States – Company Wise Molecular Diagnostics Market Share (Percent), 2010 – 2013
Figure 3–4: United States – Forecast for Company Wise Molecular Diagnostics Market Share (Percent), 2014 – 2018
Figure 3–5: United States – Molecular Diagnostics Applications Test Volume Share (Percent), 2010 – 2013
Figure 3–6: United States – Forecast for Molecular Diagnostics Applications Test Volume Share (Percent), 2014 – 2018
Figure 4–1: United States – Molecular Diagnostic Oncology Testing Market (Million US$), 2004 – 2013
Figure 4–2: United States – Forecast for Molecular Diagnostic Oncology Testing Market (Million US$), 2014 – 2018
Figure 4–3: United States – Molecular Diagnostic Breast Cancer Testing Market (Million US$), 2004 – 2013
Figure 4–4: United States – Forecast for Molecular Diagnostic Breast Cancer Testing Market (Million US$), 2014 – 2018
Figure 4–5: United States – Molecular Diagnostic Colorectal Cancer Testing Market (Million US$), 2004 – 2013
Figure 4–6: United States – Forecast for Molecular Diagnostic Colorectal Cancer Testing Market (Million US$), 2014 – 2018
Figure 4–7: United States – Molecular Diagnostic Prostate Cancer Testing Market (Million US$), 2004 – 2013
Figure 4–8: United States – Forecast for Molecular Diagnostic Prostate Cancer Testing Market (Million US$), 2014 – 2018
Figure 4–9: United States – Other Molecular Diagnostic Cancer Testing Market (Million US$), 2004 – 2013
Figure 4–10: United States – Forecast for Other Molecular Diagnostic Cancer Testing Market (Million US$), 2014 – 2018
Figure 4–11: United States – Infectious Disease Testing Market (Million US$), 2010 – 2013
Figure 4–12: United States – Forecast for Infectious Disease Testing Market (Million US$), 2014 – 2018
Figure 4–13: United States – Virology Testing Market (Million US$), 2007 – 2018
Figure 4–14: United States – Forecast for Virology Testing Market (Million US$), 2014 – 2018
Figure 4–15: United States – HPV Testing Market (Million US$), 2004 – 2013
Figure 4–16: United States – Forecast for HPV Testing Market (Million US$), 2014 – 2018
Figure 4–17: United States – HAI Testing Market (Million US$), 2010 – 2013
Figure 4–18: United States – Forecast for HAI Testing Market (Million US$), 2014 – 2018
Figure 4–19: United States – Critical Care Testing Market (Million US$), 2010 – 2013
Figure 4–20: United States – Forecast for Critical Care Testing Market (Million US$), 2014 – 2018
Figure 4–21: United States – Genetic Testing Market (Million US$), 2010 – 2013
Figure 4–22: United States – Forecast for Genetic Testing Market (Million US$), 2014 – 2018
Figure 4–23: United States – Blood Screening Market (Million US$), 2006 – 2013
Figure 4–24: United States – Forecast for Blood Screening Market (Million US$), 2014 – 2018
Figure 4–25: United States – Food Pathogen Testing Market (Million US$), 2010 – 2013
Figure 4–26: United States – Forecast for Food Pathogen Testing Market (Million US$), 2014 – 2018
Figure 4–27: United States – HLA Testing Market (Million US$), 2008 – 2013
Figure 4–28: United States – Forecast for HLA Testing Market (Million US$), 2014 – 2018
Figure 5–1: United States – Oncology Test Volume (Million), 2004 – 2013
Figure 5–2: United States – Forecast for Oncology Test Volume (Million), 2014 – 2018
Figure 5–3: United States – Breast Cancer Test Volume (Million), 2004 – 2013
Figure 5–4: United States – Forecast for Breast Cancer Test Volume (Million), 2014 – 2018
Figure 5–5: United States – Colorectal Cancer Test Volume (Million), 2004 – 2013
Figure 5–6: United States – Forecast for Colorectal Cancer Test Volume (Million), 2014 – 2018
Figure 5–7: United States – Prostate Cancer Test Volume (Million), 2004 – 2013
Figure 5–8: United States – Forecast for Prostate Cancer Test Volume (Million), 2014 – 2018
Figure 5–9: United States – Other Cancer Test Volume (Million), 2004 – 2013
Figure 5–10: United States – Forecast for Other Cancer Test Volume (Million), 2014 – 2018
Figure 5–11: United States – Infectious Disease Test Volume (Million), 2010 – 2013
Figure 5–12: United States – Forecast for Infectious Disease Test Volume (Million), 2014 – 2018
Figure 5–13: United States – Virology Test Volume (Million), 2007 – 2018
Figure 5–14: United States – Forecast for Virology Test Volume (Million), 2014 – 2018
Figure 5–15: United States – HPV Test Volume (Million), 2004 – 2013
Figure 5–16: United States – Forecast for HPV Test Volume (Million), 2014 – 2018
Figure 5–17: United States – HAI Test Volume (Million), 2010 – 2013
Figure 5–18: United States – Forecast for HAI Test Volume (Million), 2014 – 2018
Figure 5–19: United States – Critical Care Test Volume (Million), 2010 – 2013
Figure 5–20: United States – Forecast for Critical Care Test Volume (Million), 2014 – 2018
Figure 5–21: United States – Genetic Testing Test Volume (Million), 2010 – 2013
Figure 5–22: United States – Forecast for Genetic Testing Test Volume (Million), 2014 – 2018
Figure 5–23: United States – Blood Screening Test Volume (Million), 2006 – 2013
Figure 5–24: United States – Forecast for Blood Screening Test Volume (Million), 2014 – 2018
Figure 5–25: United States – Food Pathogen Test Volume (Million), 2010 – 2013
Figure 5–26: United States – Forecast for Food Pathogen Test Volume (Million), 2014 – 2018
Figure 5–27: United States – HLA Test Volume (Million), 2008 – 2013
Figure 5–28: United States – Forecast for HLA Test Volume (Million), 2014 – 2018
Figure 6–1: Roche – United States Molecular Diagnostic Sales (Million US$), 2008 – 2013
Figure 6–2: Roche – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–3: Abbott Laboratories – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–4: Abbott Laboratories – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–5: Myriad Genetics – United States Molecular Diagnostic Sales (Million US$), 2007 – 2013
Figure 6–6: Myriad Genetics – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–7: Biomerieux – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–8: Biomerieux – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–9: Qiagen – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–10: Qiagen – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–11: Hologic–Gen–Probe – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–12: Hologic–Gen–Probe – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–13: Becton Dickinson – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–14: Becton Dickinson – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–15: Siemens – United States Molecular Diagnostic Sales (Million US$), 2008 – 2013
Figure 6–16: Siemens – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–17: Cepheid – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–18: Cepheid – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–19: Others – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–20: Others – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 7–1: United States – Investment in the Human Genome Project (Billion US$), 2003, 2012
Figure 2–1: United States – Molecular Diagnostics Market (Million US$), 2010 – 2013
Figure 2–2: United States – Forecast for Molecular Diagnostics Market (Million US$), 2014 – 2018
Figure 2–3: United States – Molecular Diagnostics Test Volume (Million), 2010 – 2013
Figure 2–4: United States – Forecast for Molecular Diagnostics Test Volume (Million), 2014 – 2018
Figure 3–1: United States – Molecular Diagnostics Applications Market Share (Percent), 2010 – 2013
Figure 3–2: United States – Forecast for Molecular Diagnostics Applications Market Share (Percent), 2014 – 2018
Figure 3–3: United States – Company Wise Molecular Diagnostics Market Share (Percent), 2010 – 2013
Figure 3–4: United States – Forecast for Company Wise Molecular Diagnostics Market Share (Percent), 2014 – 2018
Figure 3–5: United States – Molecular Diagnostics Applications Test Volume Share (Percent), 2010 – 2013
Figure 3–6: United States – Forecast for Molecular Diagnostics Applications Test Volume Share (Percent), 2014 – 2018
Figure 4–1: United States – Molecular Diagnostic Oncology Testing Market (Million US$), 2004 – 2013
Figure 4–2: United States – Forecast for Molecular Diagnostic Oncology Testing Market (Million US$), 2014 – 2018
Figure 4–3: United States – Molecular Diagnostic Breast Cancer Testing Market (Million US$), 2004 – 2013
Figure 4–4: United States – Forecast for Molecular Diagnostic Breast Cancer Testing Market (Million US$), 2014 – 2018
Figure 4–5: United States – Molecular Diagnostic Colorectal Cancer Testing Market (Million US$), 2004 – 2013
Figure 4–6: United States – Forecast for Molecular Diagnostic Colorectal Cancer Testing Market (Million US$), 2014 – 2018
Figure 4–7: United States – Molecular Diagnostic Prostate Cancer Testing Market (Million US$), 2004 – 2013
Figure 4–8: United States – Forecast for Molecular Diagnostic Prostate Cancer Testing Market (Million US$), 2014 – 2018
Figure 4–9: United States – Other Molecular Diagnostic Cancer Testing Market (Million US$), 2004 – 2013
Figure 4–10: United States – Forecast for Other Molecular Diagnostic Cancer Testing Market (Million US$), 2014 – 2018
Figure 4–11: United States – Infectious Disease Testing Market (Million US$), 2010 – 2013
Figure 4–12: United States – Forecast for Infectious Disease Testing Market (Million US$), 2014 – 2018
Figure 4–13: United States – Virology Testing Market (Million US$), 2007 – 2018
Figure 4–14: United States – Forecast for Virology Testing Market (Million US$), 2014 – 2018
Figure 4–15: United States – HPV Testing Market (Million US$), 2004 – 2013
Figure 4–16: United States – Forecast for HPV Testing Market (Million US$), 2014 – 2018
Figure 4–17: United States – HAI Testing Market (Million US$), 2010 – 2013
Figure 4–18: United States – Forecast for HAI Testing Market (Million US$), 2014 – 2018
Figure 4–19: United States – Critical Care Testing Market (Million US$), 2010 – 2013
Figure 4–20: United States – Forecast for Critical Care Testing Market (Million US$), 2014 – 2018
Figure 4–21: United States – Genetic Testing Market (Million US$), 2010 – 2013
Figure 4–22: United States – Forecast for Genetic Testing Market (Million US$), 2014 – 2018
Figure 4–23: United States – Blood Screening Market (Million US$), 2006 – 2013
Figure 4–24: United States – Forecast for Blood Screening Market (Million US$), 2014 – 2018
Figure 4–25: United States – Food Pathogen Testing Market (Million US$), 2010 – 2013
Figure 4–26: United States – Forecast for Food Pathogen Testing Market (Million US$), 2014 – 2018
Figure 4–27: United States – HLA Testing Market (Million US$), 2008 – 2013
Figure 4–28: United States – Forecast for HLA Testing Market (Million US$), 2014 – 2018
Figure 5–1: United States – Oncology Test Volume (Million), 2004 – 2013
Figure 5–2: United States – Forecast for Oncology Test Volume (Million), 2014 – 2018
Figure 5–3: United States – Breast Cancer Test Volume (Million), 2004 – 2013
Figure 5–4: United States – Forecast for Breast Cancer Test Volume (Million), 2014 – 2018
Figure 5–5: United States – Colorectal Cancer Test Volume (Million), 2004 – 2013
Figure 5–6: United States – Forecast for Colorectal Cancer Test Volume (Million), 2014 – 2018
Figure 5–7: United States – Prostate Cancer Test Volume (Million), 2004 – 2013
Figure 5–8: United States – Forecast for Prostate Cancer Test Volume (Million), 2014 – 2018
Figure 5–9: United States – Other Cancer Test Volume (Million), 2004 – 2013
Figure 5–10: United States – Forecast for Other Cancer Test Volume (Million), 2014 – 2018
Figure 5–11: United States – Infectious Disease Test Volume (Million), 2010 – 2013
Figure 5–12: United States – Forecast for Infectious Disease Test Volume (Million), 2014 – 2018
Figure 5–13: United States – Virology Test Volume (Million), 2007 – 2018
Figure 5–14: United States – Forecast for Virology Test Volume (Million), 2014 – 2018
Figure 5–15: United States – HPV Test Volume (Million), 2004 – 2013
Figure 5–16: United States – Forecast for HPV Test Volume (Million), 2014 – 2018
Figure 5–17: United States – HAI Test Volume (Million), 2010 – 2013
Figure 5–18: United States – Forecast for HAI Test Volume (Million), 2014 – 2018
Figure 5–19: United States – Critical Care Test Volume (Million), 2010 – 2013
Figure 5–20: United States – Forecast for Critical Care Test Volume (Million), 2014 – 2018
Figure 5–21: United States – Genetic Testing Test Volume (Million), 2010 – 2013
Figure 5–22: United States – Forecast for Genetic Testing Test Volume (Million), 2014 – 2018
Figure 5–23: United States – Blood Screening Test Volume (Million), 2006 – 2013
Figure 5–24: United States – Forecast for Blood Screening Test Volume (Million), 2014 – 2018
Figure 5–25: United States – Food Pathogen Test Volume (Million), 2010 – 2013
Figure 5–26: United States – Forecast for Food Pathogen Test Volume (Million), 2014 – 2018
Figure 5–27: United States – HLA Test Volume (Million), 2008 – 2013
Figure 5–28: United States – Forecast for HLA Test Volume (Million), 2014 – 2018
Figure 6–1: Roche – United States Molecular Diagnostic Sales (Million US$), 2008 – 2013
Figure 6–2: Roche – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–3: Abbott Laboratories – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–4: Abbott Laboratories – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–5: Myriad Genetics – United States Molecular Diagnostic Sales (Million US$), 2007 – 2013
Figure 6–6: Myriad Genetics – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–7: Biomerieux – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–8: Biomerieux – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–9: Qiagen – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–10: Qiagen – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–11: Hologic–Gen–Probe – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–12: Hologic–Gen–Probe – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–13: Becton Dickinson – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–14: Becton Dickinson – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–15: Siemens – United States Molecular Diagnostic Sales (Million US$), 2008 – 2013
Figure 6–16: Siemens – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–17: Cepheid – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–18: Cepheid – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 6–19: Others – United States Molecular Diagnostic Sales (Million US$), 2010 – 2013
Figure 6–20: Others – Forecast for United States Molecular Diagnostic Sales (Million US$), 2014 – 2018
Figure 7–1: United States – Investment in the Human Genome Project (Billion US$), 2003, 2012
